Slingshot members are tracking this event:
Agios Pharma (AGIO) to report data from Phase 2 study of AG-348 in patients with PK deficiency in at European Hematology Association Meeting
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
Slingshot Insights Explained
Jun 11, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Interim Data, Phase 2a Interim Data, Ag-348, Pk Deficiency, European Hematology Association, Pyruvate Kinase Deficiency, Open-label